132 related articles for article (PubMed ID: 533396)
1. Removal of endogenous middle molecules by hemoperfusion.
Asaba H; Bergström J; Fürst P; Gunnarsson B; Neuhauser M; Oulès R; Yahiel V
Artif Organs; 1979 May; 3(2):132-6. PubMed ID: 533396
[TBL] [Abstract][Full Text] [Related]
2. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
[TBL] [Abstract][Full Text] [Related]
3. The use of hemoperfusion as an adjunct to hemodialysis.
Trafford A; Ireland R; Evans R
Artif Organs; 1979 Aug; 3(3):249-52. PubMed ID: 533415
[TBL] [Abstract][Full Text] [Related]
4. Hemoperfusion with uncoated amberlite XE-336 resin in normal and uremic dogs.
Rosenbaum JL; Kramer MS; Raja R
Nephron; 1978; 21(1):27-37. PubMed ID: 662054
[TBL] [Abstract][Full Text] [Related]
5. The effect of hemodialysis on endogenous middle molecules in uremic patients.
Asaba H; Fürst P; Oulés R; Yahiel V; Zimmerman L; Bergström J
Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
[TBL] [Abstract][Full Text] [Related]
6. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
[TBL] [Abstract][Full Text] [Related]
7. The removal of uremic small and middle molecules and free amino acids by carbon hemoperfusion.
Oulès R; Asaba H; Neuhäuser M; Yahiel V; Gunnarsson B; Bergström J; Fürst P
Trans Am Soc Artif Intern Organs; 1977; 23():583-90. PubMed ID: 910385
[No Abstract] [Full Text] [Related]
8. Improvement of continuous arteriovenous hemofiltration (CAVH) and hemofiltration (HF) efficiency by adding hemoperfusion (HP).
Marangoni R; Civardi F; Masi F; Avanzi C; Savino R; Manfredi A; Cimino R
Biomater Artif Cells Artif Organs; 1990; 18(4):541-8. PubMed ID: 2285819
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical assessment of combined ACAC hemoperfusion-ultrafiltration in uremia.
Chang TM; Chirito E; Barre P; Cole C; Lister C; Resurreccion E
Artif Organs; 1979 May; 3(2):127-31. PubMed ID: 533395
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo.
Sombolos K; Tsitamidou Z; Kyriazis G; Karagianni A; Kantaropoulou M; Progia E
Am J Nephrol; 1997; 17(5):406-12. PubMed ID: 9382156
[TBL] [Abstract][Full Text] [Related]
11. Adsorption of Protein-Bound Uremic Toxins Using Activated Carbon through Direct Hemoperfusion in vitro.
Yamamoto S; Ito T; Sato M; Goto S; Kazama JJ; Gejyo F; Narita I
Blood Purif; 2019; 48(3):215-222. PubMed ID: 31055586
[TBL] [Abstract][Full Text] [Related]
12. Removal of uremic waste metabolites from the intestinal tract by encapsulated carbon and oxidized starch.
Sparks RE; Mason NS; Meier PM; Litt MH; Lindan O
Trans Am Soc Artif Intern Organs; 1971; 17():229-38. PubMed ID: 5158097
[No Abstract] [Full Text] [Related]
13. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
Trznadel K; Kidawa Z; Walasek L; Lutz W
Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
[No Abstract] [Full Text] [Related]
14. Clinical implications of uremic middle molecules in regular hemodialysis patients.
Asaba H; Alvestrand A; Fürst P; Bergström J
Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
[TBL] [Abstract][Full Text] [Related]
15. Uremic middle molecules exist and are biologically active.
Bergström J; Fürst P; Zimmerman L
Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
[No Abstract] [Full Text] [Related]
16. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
Li J; Li D; Xu Y; Wang A; Xu C; Yu C
Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
[TBL] [Abstract][Full Text] [Related]
17. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
[TBL] [Abstract][Full Text] [Related]
18. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
[TBL] [Abstract][Full Text] [Related]
19. Multicentric experience with combined hemodialysis/hemoperfusion in chronic uremia.
Bonomini V; Stefoni S; Casciani CU; Taccone Gallucci M; Albertazzi A; Cappelli P; Mioli V; Boggi R; Mastrangelo F; Rizzelli S
Contrib Nephrol; 1982; 29():133-42. PubMed ID: 7075212
[TBL] [Abstract][Full Text] [Related]
20. Middle molecule accumulation in uremia: an "extra uremic factor".
Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
